Acuta Capital Partners, LLC Rezolute, Inc. Transaction History

Acuta Capital Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.32 - $2.1 $83,688 - $133,140	-63,400 Reduced 16.98%	310,000 $409,000
Q2 2023 Aug 14, 2023	BUY	$1.75 - $2.33 $12,593 - $16,766	7,196 Added 1.97%	373,400 $739,000
Q1 2023 May 15, 2023	SELL	$1.79 - $2.87 $96,294 - $154,394	-53,796 Reduced 12.81%	366,204 $703,000
Q4 2022 Feb 14, 2023	BUY	$1.38 - $2.84 $1,179 - $2,428	855 Added 0.2%	420,000 $869,000
Q3 2022 Nov 14, 2022	SELL	$2.19 - $3.49 $494,920 - $788,708	-225,991 Reduced 35.03%	419,145 $1.15 Million
Q2 2022 Aug 15, 2022	BUY	$2.6 - $3.85 $1.68 Million - $2.48 Million	645,136 New	645,136 $2.08 Million

38.5M

1.6K

24.6K

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $171M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.